Show simple item record

dc.contributor.authorPatel, NS
dc.contributor.authorDobbie, MS
dc.contributor.authorRochester, M
dc.contributor.authorSteers, G
dc.contributor.authorPoulsom, R
dc.contributor.authorLe Monnier, K
dc.contributor.authorCranston, DW
dc.contributor.authorLi, J-L
dc.contributor.authorHarris, AL
dc.date.accessioned2017-11-27T16:26:11Z
dc.date.available2017-11-27T16:26:11Z
dc.date.issued2006-08-15
dc.identifier.issn1078-0432
dc.identifier.issn1557-3265
dc.identifier.urihttp://hdl.handle.net/10026.1/10305
dc.description.abstract

<jats:title>Abstract</jats:title> <jats:p>Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis.</jats:p> <jats:p>Experimental Design: The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and α-smooth muscle actin (α-SMA) using conventional immunohistochemistry.</jats:p> <jats:p>Results: The expression of DLL4 was significantly up-regulated in superficial (P &amp;lt; 0.01) and invasive (P &amp;lt; 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 (P &amp;lt; 0.001) and VEGF (P &amp;lt; 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of α-SMA, 98.7% of DLL4-positive tumor vessels coexpressed α-SMA, compared with 64.5% of DLL4-negative tumor vessels (P &amp;lt; 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder.</jats:p> <jats:p>Conclusion: DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.</jats:p>

dc.format.extent4836-4844
dc.format.mediumPrint
dc.languageen
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research (AACR)
dc.subjectActins
dc.subjectAdaptor Proteins, Signal Transducing
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntigens, CD34
dc.subjectCalcium-Binding Proteins
dc.subjectCarcinoma, Transitional Cell
dc.subjectCohort Studies
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunohistochemistry
dc.subjectIntercellular Signaling Peptides and Proteins
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectNeovascularization, Pathologic
dc.subjectPolymerase Chain Reaction
dc.subjectPrognosis
dc.subjectUp-Regulation
dc.subjectUrinary Bladder Neoplasms
dc.subjectVascular Endothelial Growth Factor A
dc.titleUp-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer
dc.typejournal-article
dc.typeArticle
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/16914569
plymouth.issue16
plymouth.volume12
plymouth.publication-statusPublished
plymouth.journalClinical Cancer Research
dc.identifier.doi10.1158/1078-0432.ccr-06-0285
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine
dc.publisher.placeUnited States
dc.identifier.eissn1557-3265
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1158/1078-0432.ccr-06-0285
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV